Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage
Major shipping companies are investing millions of dollars to upgrade their cold-chain infrastructure. As GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound surge in popularity, logistics giants are racing to meet the specific storage requirements of these temperature-sensitive drugs. Injectable biologics risk losing their efficacy if they are exposed to incorrect temperatures during transit, making specialized storage a primary focus for carriers.
UPS recently committed $48 million toward new temperature-controlled facilities, citing a shift toward specialized therapies and care delivered outside of traditional hospital settings. Similarly, FedEx launched a dedicated life sciences organization earlier this month, reporting nearly $10 billion in healthcare transportation revenue for fiscal year 2026. These companies now view healthcare logistics as a critical growth engine rather than just another service category.
Smaller providers and industry veterans like C.H. Robinson and DHL are also making moves to stay relevant. C.H. Robinson surpassed $1 billion in healthcare revenue last year, while DHL committed to investing 2 billion euros into health logistics by 2030. The industry focus is on end-to-end visibility and predictive technology to ensure that medicines remain stable from the warehouse to the patient.
Regulatory agencies remain vigilant regarding this transition. The FDA warns that patients should avoid any medication that arrives warm or improperly refrigerated. Because the supply of refrigerated transport capacity is currently constrained, the pressure is on these logistics networks to ensure reliability and strict temperature control for every delivery.